GILD
Gilead Sciences, Inc. · Healthcare · Drug Manufacturers - General
Señales de momentum (gestores comparables): amplitud de titulares 0.0% · flujo de acciones -5.6% · nuevas posiciones netas 0.0% · fórmula
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q1 2025
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q3 2026 | 6 | +1 | 5.67M | $830.55M | +1 | n/a |
| Q2 2026 | 175 | +1 | 941.63M | $119.04B | +5 | −3 |
| Q1 2026 | 176 | +4 | 930.86M | $129.53B | +6 | −3 |
| Q4 2025 | 171 | 0 | 1.00B | $122.89B | +1 | n/a |
| Q3 2025 | 23 | -1 | 603.99M | $67.03B | n/a | −2 |
| Q2 2025 | 22 | -1 | 560.26M | $62.11B | n/a | −1 |
| Q1 2025 | 20 | 0 | 255.31M | $28.60B | n/a | n/a |
| Q4 2024 | 20 | +1 | 270.33M | $24.97B | +1 | n/a |
| Q3 2024 | 18 | 0 | 213.42M | $17.89B | n/a | n/a |
| Q2 2024 | 18 | n/a | 202.41M | $13.88B | n/a | n/a |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (pasivo) | 59.52M | -1.4% | $6.67B | 0.3% | ▼ Trim | 2 | SEC ↗ |
| 2 | Capital World Investors ✦ | 53.55M | -25.3% | $6.00B | 1.0% | ▼ Trim | 4 | SEC ↗ |
| 3 | Dodge & Cox ✦ | 32.69M | -0.8% | $3.66B | 2.1% | ▼ Trim | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (pasivo) | 28.48M | +0.7% | $3.19B | 0.3% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | Wellington Management ✦ | 27.36M | -23.3% | $3.07B | 0.6% | ▼ Trim | 4 | SEC ↗ ×9 |
| 6 | Norges Bank ✦ (pasivo) | 19.86M | +2.5% | $2.22B | 0.3% | ▲ Add | 4 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 14.70M | +314.6% | $1.65B | 0.2% | ▲ Add | 4 | SEC ↗ ×2 |
| 8 | Renaissance Technologies ✦ | 5.45M | +2.3% | $610.80M | 0.9% | ▲ Add | 4 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 5.37M | +14.4% | $602.15M | 0.6% | ▲ Add | 4 | SEC ↗ ×2 |
| 10 | Millennium Management ✦ | 2.54M | +271.9% | $284.44M | 0.3% | ▲ Add | 4 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 1.86M | +2.8% | $207.37M | 0.2% | ▲ Add | 4 | SEC ↗ ×6 |
| 12 | Adage Capital Partners ✦ | 1.32M | -23.0% | $147.92M | 0.3% | ▼ Trim | 2 | SEC ↗ |
| 13 | Marshall Wace ✦ | 773.87K | -36.4% | $86.71M | 0.1% | ▼ Trim | 4 | SEC ↗ ×2 |
| 14 | Point72 Asset Management ✦ | 510.74K | -40.4% | $57.23M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 15 | Bridgewater Associates ✦ | 502.95K | +9.1% | $56.36M | 0.3% | ▲ Add | 4 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 453.76K | -55.2% | $50.84M | 0.1% | ▼ Trim | 4 | SEC ↗ ×2 |
| 17 | Gotham Asset Management ✦ | 250.99K | -2.0% | $28.12M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 18 | Arrowstreet Capital ✦ | 53.99K | -61.3% | $6.05M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 19 | Two Sigma Investments ✦ | 43.40K | -81.9% | $4.86M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 20 | Fisher Asset Management ✦ | 6.95K | -34.5% | $778,788 | 0.0% | ▼ Trim | 4 | SEC ↗ |
"Their weight" = la participación de la posición en el valor de renta variable 13F reportado por ese manager: la medida de convicción. ✦ = manager curado.
Nuevos compradores
| Sin nuevos compradores rastreados este trimestre. |
Posición cerrada
| Sin salidas rastreadas este trimestre. |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 1 tenedores, 61.30K acciones, $8,543 declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué más suelen tener los titulares rastreados de este valor: recuentos de titularidad compartida, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer · 3.00K acc. · $468,660
Officer · 3.00K acc. · $468,660
Officer · 600 acc. · $87,174
Officer · 800 acc. · $115,566
Officer · 1.60K acc. · $229,907
Officer · 3.00K acc. · $435,870
Officer, Director · 1.60K acc. · $236,014
Officer, Director · 7.99K acc. · $1.19M
Officer, Director · 5.41K acc. · $807,856
Director · 6.88K acc. · $1.02M
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología